Telix Pharmaceuticals (TLX) Intangibles (2023 - 2025)

Telix Pharmaceuticals (TLX) has disclosed Intangibles for 3 consecutive years, with $592.8 million as the latest value for Q4 2025.

  • Quarterly Intangibles rose 117.84% to $592.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $592.8 million through Dec 2025, up 117.84% year-over-year, with the annual reading at $592.8 million for FY2025, 129.9% up from the prior year.
  • Intangibles for Q4 2025 was $592.8 million at Telix Pharmaceuticals, up from $272.1 million in the prior quarter.
  • The five-year high for Intangibles was $592.8 million in Q4 2025, with the low at $71.4 million in Q4 2023.
  • Average Intangibles over 3 years is $312.1 million, with a median of $272.1 million recorded in 2024.
  • The sharpest move saw Intangibles skyrocketed 281.2% in 2024, then soared 117.84% in 2025.
  • Over 3 years, Intangibles stood at $71.4 million in 2023, then surged by 281.2% to $272.1 million in 2024, then skyrocketed by 117.84% to $592.8 million in 2025.
  • According to Business Quant data, Intangibles over the past three periods came in at $592.8 million, $272.1 million, and $71.4 million for Q4 2025, Q4 2024, and Q4 2023 respectively.